Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02096276 · ClinicalTrials.gov registry record
Boostrix® Pregnancy Registry
A clinical trial of Pertussis, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 1,517
- Enrollment target
- 1
- Study location
NCT02096276 is a study of Pertussis that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,517 participants, below the 38,822-participant average among 14 other Pertussis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02096276, a study of Pertussis, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 1,517 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this Registry is to detect and describe any abnormal pregnancy outcomes, including teratogenicity, in females intentionally or unintentionally exposed to Boostrix during their pregnancies in the US. The Registry requires voluntary, prospective reporting of eligible pregnancies by patients and health care providers (HCPs). Data such as vaccination with Boostrix during pregnancy or within 28 days preceding conception, potential confounding factors (such as exposure to other medications) and information related to the outcome of the pregnancy will be collected prospectively
Conditions Studied
Interventions
- OTHER Data collection
Study Locations (1)
North Carolina
- GSK Investigational Site - Research Triangle Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,517 participants |
| Start Date | 2014-03-31 |
| Est. Completion | 2019-08-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02096276
The ClinicalTrials.gov registry entry for NCT02096276 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,517 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 38,822-participant average among 14 other Pertussis trials with a reported enrollment target (96% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pertussis appearing as the primary indexed condition, and to 1 intervention - of which Data collection is the first listed.
NCT02096276 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02096276 about?
NCT02096276 is a clinical study titled "Boostrix® Pregnancy Registry". The purpose of this Registry is to detect and describe any abnormal pregnancy outcomes, including teratogenicity, in females intentionally or unintentionally exposed to Boostrix during their pregnancies in the US. The Registry requires voluntary, prospective reporting of eligible pregnancies by pati...
What is the current status of trial NCT02096276?
This trial is currently completed. The enrollment target is 1,517 participants. The study started on 2014-03-31. Estimated completion is 2019-08-02.
What conditions does trial NCT02096276 study?
This clinical trial studies the following conditions: Pertussis.
What interventions are being tested in trial NCT02096276?
The interventions under investigation include: Data collection (OTHER).
Who is sponsoring clinical trial NCT02096276?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02096276 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pertussis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine
COMPLETED
-
Pentavalent DTaP-Hep B-IPV
COMPLETED · Phase 2
-
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
COMPLETED · Phase 4
-
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
COMPLETED · Phase 4
-
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
COMPLETED · Phase 4
-
Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.